Lilliam Rosario

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Over the past few years, both the U.S. Food and Drug Administration (FDA) and the pharmaceutical industry have recognized the potential importance of pharmacogenomics and toxicogenomics to drug development. To resolve the uncertainties surrounding the use of microarray technology and the presentation of genomics data for regulatory purposes, several(More)
  • 1